What Tecentriq is
Tecentriq is an anti-cancer medicine that contains the active substance atezolizumab. It belongs to a group of medicines called monoclonal antibodies. A monoclonal antibody is a type of protein designed to recognise and attach to a specific target in the body.
What Tecentriq is used for
Tecentriq is used to treat adults with:
- a cancer that affects the bladder and the urinary system, called urothelial carcinoma. It is used when this cancer has:
- spread to other parts of the body
- come back after previous treatment
- or, if you cannot receive cisplatin treatment, and your doctor has tested your cancer and found high levels of a specific protein in your body called programmed death-ligand 1 (PD-L1).
- a cancer that affects the lungs, called non-small cell lung cancer. It is used when this cancer has:
- spread to other parts of the body
- come back after previous treatment.
- a cancer that affects the lungs, called non-small cell lung cancer. It is used when the cancer has:
- not spread to other parts of the body
- treatment will be given after surgery and chemotherapy
- treatment after surgery is called adjuvant therapy
- a cancer that affects the lungs, called non-small cell lung cancer. It is used when the cancer:
- you cannot receive platinum-based chemotherapy
- has spread to local parts of the lungs and to other parts of the body
- a cancer that affects the lungs, called small cell lung cancer
- A cancer that affects the breast, called triple negative breast cancer.
- A cancer of the liver which cannot be removed surgically, called hepatocellular carcinoma.
You will receive Tecentriq with another medicine called bevacizumab.
How Tecentriq works
Tecentriq works by attaching to a specific protein in your body called programmed death-ligand 1 (PD-L1). This protein suppresses the body’s immune (defence) system, thereby protecting cancer cells from being attacked by the immune cells. By attaching to the protein, Tecentriq helps your immune system to fight your cancer.